Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and with us this morning, we have Blueprint Medicines and Jeff Albers, CEO of the company.
Questions & Answers
So Jeff, to start here, AYVAKIT, your first commercial drug, was approved in December in a genetically driven subset of patients with gastrointestinal stromal tumors. Just to remind everyone, can you just start by outlining the opportunity here for this indication?
Sure. Thanks, Salveen. And on behalf of all the employees of Blueprint Medicines, thanks for including us in this virtual Goldman conference. And as always, we'll be making forward-looking statements, so we'd refer folks to our website or to the SEC documents for more detailed information.
So
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |